Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan P Venook

Showing results (101-110 of 246) with videos related to

Pageof 25
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor LocationChloe E Atreya, Claire Greene, Ryan M McWhirter, et al.
Annals of Surgical Oncology|November 17, 2007
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903Mitchell C Posner, Donna Niedzwiecki, Alan P Venook, et al.
Plos One|July 24, 2018
Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregiversChloe E Atreya, Ai Kubo, Hala T Borno, et al.
The Oncologist|May 12, 2020
Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative PatientsMatthew Susko, Chia-Ching Jackie Wang, Ann A Lazar, et al.
Cancer|June 30, 2011
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303)Andrew S Roberts, Michael J Campa, Elizabeth B Gottlin, et al.
Endocrine Connections|November 29, 2014
Bone metastases and skeletal-related events from neuroendocrine tumorsKatherine Van Loon, Li Zhang, Jennifer Keiser, et al.
Pancreas|May 13, 2016
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II TrialsPamela L Kunz, Raymond R Balise, Louis Fehrenbacher, et al.
Plos One|July 11, 2019
High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinomaDavid B Donner, Eric K Nakakura, Alan P Venook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2022
Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and CetuximabFederico Innocenti, Akram Yazdani, Naim Rashid, et al.
American Journal of Clinical Oncology|May 10, 2011
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomasAndrew H Ko, Anne M Espinoza, Kimberly A Jones, et al.
Pageof 25

Showing results (101-110 of 246) with videos related to

Sort By:
Pageof 25
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor LocationChloe E Atreya, Claire Greene, Ryan M McWhirter, et al.
Annals of Surgical Oncology|November 17, 2007
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903Mitchell C Posner, Donna Niedzwiecki, Alan P Venook, et al.
Plos One|July 24, 2018
Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregiversChloe E Atreya, Ai Kubo, Hala T Borno, et al.
The Oncologist|May 12, 2020
Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative PatientsMatthew Susko, Chia-Ching Jackie Wang, Ann A Lazar, et al.
Cancer|June 30, 2011
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303)Andrew S Roberts, Michael J Campa, Elizabeth B Gottlin, et al.
Endocrine Connections|November 29, 2014
Bone metastases and skeletal-related events from neuroendocrine tumorsKatherine Van Loon, Li Zhang, Jennifer Keiser, et al.
Pancreas|May 13, 2016
Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II TrialsPamela L Kunz, Raymond R Balise, Louis Fehrenbacher, et al.
Plos One|July 11, 2019
High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinomaDavid B Donner, Eric K Nakakura, Alan P Venook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2022
Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and CetuximabFederico Innocenti, Akram Yazdani, Naim Rashid, et al.
American Journal of Clinical Oncology|May 10, 2011
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomasAndrew H Ko, Anne M Espinoza, Kimberly A Jones, et al.
Pageof 25